Schuster Daniel, Sweeney Alex D, Stavas Mark J, Tawfik Kyrollos Y, Attia Albert, Cmelak Anthony J, Wanna George B
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN.
Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX.
Am J Otolaryngol. 2016 May-Jun;37(3):255-8. doi: 10.1016/j.amjoto.2016.01.002. Epub 2016 Feb 2.
To evaluate radiographic tumor control and treatment-related toxicity in glomus jugulare tumors treated with stereotactic radiosurgery (SRS).
Retrospective chart review.
Tertiary academic referral center.
Glomus jugulare tumors treated with SRS between 1998 and 2014 were identified. The data analysis only included patients with at least 18months of post-treatment follow up (FU).
Patients were treated with either single fraction or fractionated SRS.
Patient demographics and tumor characteristics were assessed. Radiographic control was determined by comparing pre and post treatment MRI, and was categorized as no change, regression, or progression.
Eighteen patients were treated with SRS, and 14 met inclusion criteria. Median age at treatment was 55years (range 35-79), and 71.4% of patients were female. 5 patients (35.7%) received single fraction SRS (dose range 15-18Gy), and 9 (64.3%) fractionated therapy (dose 3-7Gy×3-15 fractions). Median tumor volume was 3.78cm(3) (range 1.15-30.6). Median FU was 28.8months (range 18.6-56.1), with a mean of 31.7months. At their last recorded MRI, 7 patients (50%) had tumor stability, 6 (42.9%) had improvement, and 1 (7.1%) had progression. Disease improvement and progression rates in the single fraction group were 40% and 0%, and in the multiple-fraction group, 44.4% and 11.1%, respectively. There was no statistically significant difference in disease improvement (p=0.88) or progression (p=0.48) rates between groups (unpaired t-test).
At a median follow up of 28months, both single fraction and fractionated SRS appear to have comparable radiographic tumor control outcomes and toxicity profiles.
评估立体定向放射外科(SRS)治疗颈静脉球瘤的影像学肿瘤控制情况及治疗相关毒性。
回顾性病历审查。
三级学术转诊中心。
确定1998年至2014年间接受SRS治疗的颈静脉球瘤患者。数据分析仅纳入治疗后至少随访18个月的患者。
患者接受单次分割或分次SRS治疗。
评估患者人口统计学和肿瘤特征。通过比较治疗前后的MRI确定影像学控制情况,并分为无变化、消退或进展。
18例患者接受了SRS治疗,14例符合纳入标准。治疗时的中位年龄为55岁(范围35 - 79岁),71.4%的患者为女性。5例患者(35.7%)接受单次分割SRS(剂量范围15 - 18Gy),9例(64.3%)接受分次治疗(剂量3 - 7Gy×3 - 15次分割)。中位肿瘤体积为3.78cm³(范围1.15 - 30.6)。中位随访时间为28.8个月(范围18.6 - 56.1),平均为31.7个月。在最后一次记录的MRI检查时,7例患者(50%)肿瘤稳定,6例(42.9%)改善,1例(7.1%)进展。单次分割组的疾病改善率和进展率分别为40%和0%,多次分割组分别为44.4%和11.1%。两组之间的疾病改善率(p = 0.88)或进展率(p = 0.48)无统计学显著差异(非配对t检验)。
中位随访28个月时,单次分割和分次SRS在影像学肿瘤控制结果和毒性特征方面似乎具有可比性。